Clinical Trials Search Results Display: Title Description with: Locations Eligibility Full Trial Description Custom ? Hide Search Criteria Show Search Criteria Drug: nilotinibFind trials that include: Any drugs shown Results 1-9 of 9 for your search: Start Over Select All on Page Sort by: Phase of Trial Title Type of Trial Status of Trial Age Range Trial ID Show 10 25 50 100 200 Results per Page 1. Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Status: ActivePhase: Phase II, Phase IType: TreatmentAge: 18 and overTrial IDs: 2012-0697, NCI-2013-00551, NCT01751425 2. Nilotinib in Treating Patients with Recurrent Glioblastoma Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: 091728, NCI-2010-01839, NCI-2012-02871, NCT01140568 3. Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, TreatmentAge: 21 to 69Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216 4. Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients Status: ActivePhase: Phase IIType: TreatmentAge: 18 and overTrial IDs: CAMN107I2201, NCI-2013-01189, NCT01784068 5. Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: MC1284, NCI-2013-00469, 12-006178, NCT01806571 6. Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, TreatmentAge: 17 and overTrial IDs: Winship3143-16, NCI-2016-00162, IRB00087045, NCT02709083 7. Nilotinib and Cetuximab in Treating Patients With Solid Tumors That Can Be Treated With Cetuximab Status: Not yet activePhase: Phase IType: TreatmentAge: 18 and overTrial IDs: 2013-0039, NCI-2013-01168, NCT01871311 8. Nilotinib and Paclitaxel in Treating Patients with Refractory Solid Tumors Status: ActivePhase: Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 18 and overTrial IDs: 15-C-0086, NCI-2014-00688, 9659, NCT02379416 9. Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia Status: ActivePhase: Phase IType: Biomarker/Laboratory analysis, TreatmentAge: 21 to 64Trial IDs: IRB00011766, NCI-2016-00083, NCT02779283 Select All on Page Start Over
